Physician profile
Sam V Truong
NPI 1841516689
$3,412.99
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $321 · 2021: $1,105 · 2022: $1,172 · 2024: $17.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $864.15 | 2019-2022 | |
| Abbvie INC. | $704.50 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $324.25 | 2019-2022 | |
| Janssen Biotech, INC. | $255.77 | 2019-2022 | |
| Leo Pharma INC. | $253.12 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $165.73 | 2021-2022 | |
| Genzyme Corporation | $158.09 | 2021-2022 | |
| Allergan, INC. | $120.76 | 2019-2022 | |
| Incyte Corporation | $107.36 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $77.30 | 2021 | |
| Sun Pharmaceutical Industries INC. | $64.91 | 2019-2021 | |
| Ucb, INC. | $55.29 | 2021 | |
| Biofrontera INC. | $54.33 | 2019 | |
| Lilly USA, LLC | $52.38 | 2019-2022 | |
| Amgen INC. | $33.83 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $27.51 | 2022 | |
| Misonix INC | $20.76 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.62 | 2021 | |
| Galderma Laboratories, L.P. | $15.47 | 2020 | |
| Bioventus LLC | $13.85 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.57 | 2022 | |
| Icad, INC | $12.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Truong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.